Exchange: NASDAQ·Updated 07:30 PM EST

KNSA News

News
all
press releases
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Average Price Target of $100.57 According to Brokerages
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a b...
MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Average Price Target of $100.57 According to Brokerages
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a b...
MarketBeat
More News
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earningsread more...
Benzinga
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Zacks
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Zacks
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Zacks
TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Zacks
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks

Advertisement|Remove ads.